Format

Send to

Choose Destination
Curr Opin Genet Dev. 2017 Feb;42:8-13. doi: 10.1016/j.gde.2016.12.002. Epub 2017 Jan 6.

The ageing genome, clonal mosaicism and chronic disease.

Author information

1
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892-9776, United States.
2
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892-9776, United States. Electronic address: chanocks@mail.nih.gov.

Abstract

Clonal mosaicism arises when a postzygotic mutational event is detectable in subpopulations of cells as an alternative genotype while not present in the germline genome. Although described in a subset of pediatric disorders, new genomic technologies have detected higher than anticipated frequencies of clonal mosaicism in adult population studies, stimulating investigation as to how clonal mosaicism could contribute to chronic human diseases, such as cancer, diabetes and neurodegenerative disorders. It has also been postulated to be an important mechanism for functional cellular diversity, including the brain. Early studies have characterized the spectrum of detectable mosaic alterations and have begun to investigate whether detectable mosaicism could be important as an overall biomarker for risk or in the case of hematologic cancers, identification of preleukemic clones.

PMID:
28068559
PMCID:
PMC5446794
DOI:
10.1016/j.gde.2016.12.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center